文献速递胸部肿瘤放疗放疗物理与技术

局部晚期胸部恶性肿瘤同步放化疗中淋巴细胞最低值与恢复动态:危及器官约束的建立

Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: Establishment of organs-at-risk constraints.
PubMed 文献 · Radiother Oncol · 2025-06-26

本研究基于2013至2022年两个独立队列(III期非小细胞肺癌和II至III期食管癌接受放化疗患者),探讨放疗后绝对淋巴细胞计数最低值及恢复指数对总生存和无进展生存的独立预后价值,并确定与淋巴细胞保护相关的危及器官剂量约束。结果显示高恢复指数和高淋巴细胞最低值均独立预后良好,并确定了胸椎、肋骨、肺平均剂量及脾脏等OAR的阈值。

要点

  • 放疗后淋巴细胞最低值和6个月恢复指数均独立预测胸部肿瘤放化疗患者的总生存和无进展生存。
  • 非小细胞肺癌中胸椎V35Gy≤25.5%和肋骨V35Gy≤6.6%与淋巴细胞恢复指数相关。
  • 食管癌中胸椎V35Gy≤25.7%、MLD≤10.6 Gy和脾脏V5Gy≤7.2%与淋巴细胞最低值或恢复相关。

核心结论

  • 放疗后淋巴细胞最低值和恢复指数均对胸部恶性肿瘤患者的生存结局有重要影响。
  • 未来需前瞻性研究验证遵守本研究所建立的淋巴细胞保护性OAR约束能否改善淋巴细胞减少和结局。

研究设计与样本

  • 研究分析了两个独立队列:III期非小细胞肺癌和II至III期食管癌患者,均接受放化疗,时间跨度为2013至2022年。
  • 淋巴细胞最低值定义为放疗期间最低的绝对淋巴细胞计数;恢复指数为放疗后6个月ALC与放疗前ALC的比值。
  • 评估ALC最低值和恢复指数对总生存和无进展生存的影响,并将OAR放疗剂量与ALC最低值和恢复指数进行相关性分析以确定阈值。

主要发现

  • 在两个队列中,高恢复指数和高ALC最低值均独立预后良好,与改善的总生存和无进展生存相关。
  • 非小细胞肺癌中,胸椎V35Gy和肋骨V35Gy与恢复指数相关;胸椎V20Gy和平均肺剂量与ALC最低值相关。
  • 食管癌中,胸椎V35Gy与恢复指数相关;平均肺剂量和脾脏V5Gy与ALC最低值相关。

关键数值与推荐

  • 非小细胞肺癌:胸椎V35Gy截止值为25.5%,肋骨V35Gy截止值为6.6%,平均肺剂量截止值为16.5 Gy,胸椎V20Gy截止值为25.6%。
  • 食管癌:胸椎V35Gy截止值为25.7%,平均肺剂量截止值为10.6 Gy,脾脏V5Gy截止值为7.2%。

临床怎么用

  • 在制定胸部肿瘤放疗计划时,可参考本研究所确定的OAR剂量约束(如胸椎V35Gy、肋骨V35Gy、平均肺剂量、脾脏V5Gy等)以减轻淋巴细胞减少。
  • 关注放疗后6个月淋巴细胞恢复情况,对高恢复指数患者可能预示更好生存。

局限性

  • 研究为回顾性分析,结论需前瞻性研究验证。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiotherapy-induced-lymphopenia (RIL) worsens outcome in thoracic malignancies on radiotherapy (RT). We hypothesised that post-RT absolute lymphocyte count (ALC) nadir and recovery were independently prognostic for overall survival (OS) and progression-free survival (PFS) in thoracic malignancies following radical chemo-irradiation. We also aimed to determine relevant organs-at-risk (OARs) constraints. METHODS AND MATERIALS: Two independent cohorts of stage III non-small-cell lung cancer (NSCLC) and stage II to III oesophageal cancer (EC) patients receiving chemo-irradiation from 2013 to 2022 were analysed. ALC nadir was defined as the lowest ALC on RT. ALC recovery index (ARI) was the ALC at 6 months/Pre-RT ALC. Effect of ALC nadir and ARI on OS and PFS were evaluated. RT dose of OARs was correlated with ALC nadir and ARI. OAR thresholds were then determined. RESULTS: High ARI and ALC nadir were independently prognostic of improved OS and PFS for both cohorts. In NSCLC, thoracic spine V35Gy and ribs V35Gy were associated with ARI. Cut-off for thoracic spine V35Gy was 25.5 % while ribs V35Gy cut-off was 6.6 %. Thoracic spine V20Gy and Mean lung dose (MLD) were associated with ALC nadir in NSCLC. MLD cut-off was 16.5 Gy while T spine V20Gy cut off was 25.6 %. For EC, thoracic spine V35Gy was also associated with ARI. Similar to NSCLC, cut-off was 25.7 %. MLD and spleen V5Gy were associated with ALC nadir. MLD and Spleen V5Gy cut-off was 10.6 Gy and 7.2 % respectively. CONCLUSION: Post-RT lymphocyte nadir and recovery were both important for survival outcomes. Future prospective studies are warranted to validate whether abiding to lymphocyte sparing OARs constraints developed in the current study can improve lymphopenia and outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cheung BMF, Yuen KK, Luk MY, et al. Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: Establishment of organs-at-risk constraints. Radiother Oncol. 2025. PMID: 40581215. doi:10.1016/j.radonc.2025.111009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。